Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn’s Disease

ABSTRACT: Abstract

Background

A previously developed clinical decision support tool (CDST) identified patients with Crohn’s disease (CD) most likely to respond to vedolizumab. This study evaluated the ability of the CDST to predict real-world healthcare resource utilization (HRU).

Methods

The Optum and Truven healthcare databases were searched for patients with CD treated with vedolizumab (Optum, n = 358; Truven, n = 1445) or an anti-tumor necrosis factor (TNF) agent (Optum, n = 814). Patients were stratified using the 5-variable (prior bowel surgery, prior fistulizing disease, prior anti-TNF exposure, albumin, C-reactive protein) and a new modified 3-variable (without laboratory data) CDST. Annualized expenditures and HRU were compared with both CDSTs across response probability g

SUBMITTER:  

PROVIDER: S-EPMC9802432 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature